{"id":4405,"date":"2020-08-28T08:26:04","date_gmt":"2020-08-28T08:26:04","guid":{"rendered":"https:\/\/maat.swebwp.oci.eu\/?p=4405"},"modified":"2023-09-25T13:59:53","modified_gmt":"2023-09-25T13:59:53","slug":"maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt","status":"publish","type":"post","link":"https:\/\/maat.swebwp.oci.eu\/fr\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/","title":{"rendered":"MaaT Pharma to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at Virtual 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)"},"content":{"rendered":"[vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1″ background_hover_color_opacity=\u00a0\u00bb1″ column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ width=\u00a0\u00bb1\/6″ tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1″ background_hover_color_opacity=\u00a0\u00bb1″ column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ width=\u00a0\u00bb2\/3″ tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][vc_column_text]\n

— Data from the Company\u2019s compassionate use program with MaaT013 as a treatment in patients with intestinal acute Graft-versus-Host-Disease will be highlighted in an e-poster presentation —<\/strong><\/p>\n

— MaaT013 is an enema formulation of a microbiota biotherapeutic characterized by a high diversity and consistent richness of microbial species derived from pooled healthy donors —<\/strong><\/p>\n

— Results will be announced on Monday, August 31 —<\/strong><\/p>\n[\/vc_column_text][vc_column_text]Lyon, France, August 28, 2020 \u2013<\/strong> MaaT Pharma announced today that clinical data from 11 patients treated with the company\u2019s lead microbiome restoration biotherapeutic, MaaT013, will be presented in an e-poster at the 46th<\/sup> Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) to be held virtually from August 29 \u2013 September 1, 2020. MaaT013 is an enema formulation of a microbiota biotherapeutic characterized by a consistent richness of microbial species derived from pooled healthy donors to treat patients with intestinal acute Graft-versus-Host-Disease (aGvHD) following allogeneic Hematopoietic Stem-Cell Transplantation (allo-HSCT). MaaT Pharma provided MaaT013 to hospitals as part of its compassionate use program for patients who had previously received and failed up to five previous systemic treatments for GvHD. MaaT Pharma will announce the results through a press release on Monday, August 31, 2020.<\/p>\n

 <\/p>\n

As the event is held virtually this year, the presentation will take the form of an e-poster with commentary. The abstract of the presentation is available using the following link, https:\/\/www.professionalabstracts.com\/ebmt2020\/iPlanner\/#\/presentation\/5171<\/a>.<\/p>\n

 <\/p>\n

e-Poster presentation details:<\/strong><\/p>\n

Title: <\/strong>Successful and Safe Treatment of Intestinal Graft-Versus-Host Disease (GvHD) with Pooled-Donor Full Ecosystem Microbiota Biotherapeutics<\/p>\n

Session Name: <\/strong>e-Experimental Transplantation<\/p>\n

Date\/Time: <\/strong>Saturday, August 29, 2020 \/ 12:30 PM \u2013 06:30 PM CET<\/p>\n

Location: <\/strong>e-Poster area<\/p>\n

After the e-presentation, MaaT Pharma will provide the poster on the company website under \u201cNews\u201d.<\/p>\n

In addition to the compassionate use program, MaaT Pharma is currently investigating MaaT013 in a multi-center, single-arm, open-label, Phase II clinical trial called HERACLES to evaluate the safety and efficacy of MaaT013 in gastrointestinal-predominant, steroid-refactory, acute GvHD (GI SR-aGvHD) patients (NCT03359980<\/a>). The acute form of GvHD is a serious, often fatal syndrome typically involving the gut, skin and liver. MaaT Pharma has established the most complete approach to restoring patient-microbiome symbiosis in the gut to improve efficacy of cancer treatments and survival outcomes in life-threatening diseases. MaaT013 has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).<\/p>\n[\/vc_column_text][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1″ background_hover_color_opacity=\u00a0\u00bb1″ column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ width=\u00a0\u00bb1\/6″ tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][\/vc_row][vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1″ background_hover_color_opacity=\u00a0\u00bb1″ column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ width=\u00a0\u00bb1\/1″ tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][nectar_highlighted_text color_type=\u00a0\u00bbregular\u00a0\u00bb highlight_color=\u00a0\u00bb#e9a017″ style=\u00a0\u00bbhalf_text\u00a0\u00bb]\n

About MaaT Pharma<\/strong><\/h3>\n[\/nectar_highlighted_text][vc_column_text]MaaT Pharma, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients and a Phase 2 clinical trial in acute GvHD is ongoing. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform, GutPrint\u00ae, to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to spearhead microbiome treatment integration into clinical practice.[\/vc_column_text][\/vc_column][\/vc_row][vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1″ background_hover_color_opacity=\u00a0\u00bb1″ column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ width=\u00a0\u00bb1\/4″ tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1″ background_hover_color_opacity=\u00a0\u00bb1″ column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ width=\u00a0\u00bb1\/2″ tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][nectar_btn size=\u00a0\u00bblarge\u00a0\u00bb open_new_tab=\u00a0\u00bbtrue\u00a0\u00bb button_style=\u00a0\u00bbregular\u00a0\u00bb button_color_2=\u00a0\u00bbAccent-Color\u00a0\u00bb color_override=\u00a0\u00bb#5bc0cc\u00a0\u00bb icon_family=\u00a0\u00bbiconsmind\u00a0\u00bb text=\u00a0\u00bbSee more\u00a0\u00bb margin_top=\u00a0\u00bb50″ icon_iconsmind=\u00a0\u00bbiconsmind-Mouse-Pointer\u00a0\u00bb url=\u00a0\u00bbhttps:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/09\/20200828-MaaT-EBMT-plateform-presentation-acceptance_Final.pdf\u00a0\u00bb][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1″ background_hover_color_opacity=\u00a0\u00bb1″ column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ width=\u00a0\u00bb1\/4″ tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][\/vc_row]\n","protected":false},"excerpt":{"rendered":"

[vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1″ background_hover_color_opacity=\u00a0\u00bb1″ column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ width=\u00a0\u00bb1\/6″ tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb…<\/p>\n","protected":false},"author":2,"featured_media":4369,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[21],"tags":[],"category_press":[],"year_press":[50],"class_list":{"0":"post-4405","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-communiques-de-presse-fr","8":"year_press-50"},"acf":[],"yoast_head":"\nMaaT Pharma to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at Virtual 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) - MaaT Pharma<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MaaT Pharma to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at Virtual 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) - MaaT Pharma\" \/>\n<meta property=\"og:description\" content=\"[vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1″ background_hover_color_opacity=\u00a0\u00bb1″ column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ width=\u00a0\u00bb1\/6″ tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/\" \/>\n<meta property=\"og:site_name\" content=\"MaaT Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2020-08-28T08:26:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-09-25T13:59:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2020\/08\/ebmt-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"498\" \/>\n\t<meta property=\"og:image:height\" content=\"379\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"MaaT Pharma\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"MaaT Pharma\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/\"},\"author\":{\"name\":\"MaaT Pharma\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34\"},\"headline\":\"MaaT Pharma to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at Virtual 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)\",\"datePublished\":\"2020-08-28T08:26:04+00:00\",\"dateModified\":\"2023-09-25T13:59:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/\"},\"wordCount\":1342,\"publisher\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#organization\"},\"image\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2020\/08\/ebmt-1.jpg\",\"articleSection\":[\"Communiqu\u00e9s de presse\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/\",\"url\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/\",\"name\":\"MaaT Pharma to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at Virtual 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) - MaaT Pharma\",\"isPartOf\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2020\/08\/ebmt-1.jpg\",\"datePublished\":\"2020-08-28T08:26:04+00:00\",\"dateModified\":\"2023-09-25T13:59:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/#primaryimage\",\"url\":\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2020\/08\/ebmt-1.jpg\",\"contentUrl\":\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2020\/08\/ebmt-1.jpg\",\"width\":498,\"height\":379},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/maat.swebwp.oci.eu\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MaaT Pharma to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at Virtual 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#website\",\"url\":\"https:\/\/maat.swebwp.oci.eu\/\",\"name\":\"MaaT Pharma\",\"description\":\"microbiota gut to fight cancer\",\"publisher\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/maat.swebwp.oci.eu\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#organization\",\"name\":\"Maat Pharma\",\"url\":\"https:\/\/maat.swebwp.oci.eu\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png\",\"contentUrl\":\"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png\",\"width\":150,\"height\":171,\"caption\":\"Maat Pharma\"},\"image\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34\",\"name\":\"MaaT Pharma\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MaaT Pharma to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at Virtual 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) - MaaT Pharma","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"MaaT Pharma to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at Virtual 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) - MaaT Pharma","og_description":"[vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1″ background_hover_color_opacity=\u00a0\u00bb1″ column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3″ width=\u00a0\u00bb1\/6″ tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb...","og_url":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/","og_site_name":"MaaT Pharma","article_published_time":"2020-08-28T08:26:04+00:00","article_modified_time":"2023-09-25T13:59:53+00:00","og_image":[{"width":498,"height":379,"url":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2020\/08\/ebmt-1.jpg","type":"image\/jpeg"}],"author":"MaaT Pharma","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"MaaT Pharma","Dur\u00e9e de lecture estim\u00e9e":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/#article","isPartOf":{"@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/"},"author":{"name":"MaaT Pharma","@id":"https:\/\/maat.swebwp.oci.eu\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34"},"headline":"MaaT Pharma to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at Virtual 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)","datePublished":"2020-08-28T08:26:04+00:00","dateModified":"2023-09-25T13:59:53+00:00","mainEntityOfPage":{"@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/"},"wordCount":1342,"publisher":{"@id":"https:\/\/maat.swebwp.oci.eu\/#organization"},"image":{"@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/#primaryimage"},"thumbnailUrl":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2020\/08\/ebmt-1.jpg","articleSection":["Communiqu\u00e9s de presse"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/","url":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/","name":"MaaT Pharma to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at Virtual 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) - MaaT Pharma","isPartOf":{"@id":"https:\/\/maat.swebwp.oci.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/#primaryimage"},"image":{"@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/#primaryimage"},"thumbnailUrl":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2020\/08\/ebmt-1.jpg","datePublished":"2020-08-28T08:26:04+00:00","dateModified":"2023-09-25T13:59:53+00:00","breadcrumb":{"@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/#primaryimage","url":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2020\/08\/ebmt-1.jpg","contentUrl":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2020\/08\/ebmt-1.jpg","width":498,"height":379},{"@type":"BreadcrumbList","@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/maat.swebwp.oci.eu\/fr\/"},{"@type":"ListItem","position":2,"name":"MaaT Pharma to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at Virtual 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)"}]},{"@type":"WebSite","@id":"https:\/\/maat.swebwp.oci.eu\/#website","url":"https:\/\/maat.swebwp.oci.eu\/","name":"MaaT Pharma","description":"microbiota gut to fight cancer","publisher":{"@id":"https:\/\/maat.swebwp.oci.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/maat.swebwp.oci.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/maat.swebwp.oci.eu\/#organization","name":"Maat Pharma","url":"https:\/\/maat.swebwp.oci.eu\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/maat.swebwp.oci.eu\/#\/schema\/logo\/image\/","url":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","contentUrl":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","width":150,"height":171,"caption":"Maat Pharma"},"image":{"@id":"https:\/\/maat.swebwp.oci.eu\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/maat.swebwp.oci.eu\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34","name":"MaaT Pharma"}]}},"_links":{"self":[{"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/posts\/4405","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/comments?post=4405"}],"version-history":[{"count":0,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/posts\/4405\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/media\/4369"}],"wp:attachment":[{"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/media?parent=4405"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/categories?post=4405"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/tags?post=4405"},{"taxonomy":"category_press","embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/category_press?post=4405"},{"taxonomy":"year_press","embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/year_press?post=4405"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}